About eMAX Health Systems
eMAX Health Systems was built to help life sciences teams make more confident access decisions in a market where payer other population health decision maker expectations, evidence demands, and commercialization pressures continue to evolve.
Our work combines strategic insight, research expertise, and technology-enabled engagement to support pharmaceutical and biotechnology organizations across U.S. and global markets.
Access Decisions Require More Than Isolated Inputs
Pharmaceutical teams are often working with disconnected information: payer feedback, real-world evidence, pricing models, and internal strategy discussions may happen in separate workstreams.
eMAX Health Systems helps connect those inputs into a clearer decision-making framework by combining stakeholder engagement, clinical and real-world evidence, and strategic analysis.
This connected approach supports access planning, evidence development, pricing strategy, contracting strategy, and strategy validation.
Why We're Different
Stakeholder Perspective
Access strategy is informed by payer and provider decision-makers who understand how therapies are evaluated in real-world environments.
Evidence Orientation
Our work is grounded in evidence generation and clinical context, helping teams understand treatment patterns, care decisions, utilization, and outcomes.
Strategic Application
Insights are translated into practical guidance that can support launch planning, pricing, contracting, value communication, and access optimization.
Our Leadership
Our eMAX Health Systems leadership team brings deep experience across market access, HEOR, real-world evidence, analytics, pricing, contracting, and commercialization strategy, helping manufacturers generate insight, validate strategy, and make more informed access decisions.
Eric Bishea | President
Market access insights • Commercialization strategy • Managed markets • Stakeholder engagement • MAVA® strategy
Eric leads eMAX Health Systems, including the strategic direction and operational execution of MAVA®. He brings more than three decades of experience across sales, managed markets, commercialization, healthcare data, and market access strategy, with prior leadership roles at GlobalData, EVERSANA, The Access Group, Catalyst Medical Communications, Fusion Medical Communications, Searle, Pharmacia, and Allergan. His background includes building and leading global consulting and commercialization teams that support pharmaceutical and biotech brands with competitive intelligence, market assessment, stakeholder engagement, and brand growth strategy.
Essy Mozaffari | Sr. Vice President, RWE & Medical Affairs
Real-world evidence • HEOR • Medical affairs • Market access strategy • Value demonstration
Essy leads strategy and execution for real-world evidence programs that support product differentiation, payer and regulatory decision-making, and value narrative development. He brings more than 25 years of pharmaceutical industry leadership experience across health economics, outcomes research, market access strategy, medical affairs, and commercial decision-making, with prior senior roles at Gilead Sciences, Intercept Pharmaceuticals, Chimerix, Sanofi, and Pfizer. His background includes clinical pharmacy, pharmacoeconomics, public health, health economics, and business leadership, giving clients deep expertise in generating evidence that supports access, value, and strategic decision-making.
Scott Rubin | Sr. Vice President
Market access strategy • Payer insights • Patient journey analytics • Pricing and contracting • Commercialization execution
Scott leads customized market access strategy development for eMAX Health Systems, helping manufacturers connect payer insight, patient journey analytics, and commercialization strategy. He brings experience across biopharmaceutical consulting, market analytics, pricing, distribution strategy, patient support program design, oncology clinic access, value-based contracting, and portfolio access measurement. His prior roles at Precision AQ, Blue Fin Group, and Eli Lilly give him a well-rounded perspective across strategy and execution, supporting manufacturers as they work to improve patient access and brand performance.
Gary Lebovics, MPH | Sr. Vice President, Insight & Analytics
Insight and analytics • Pricing and contracting • HEOR • Real-world data • Budget impact modeling
Gary leads eMAX Health’s Insight and Analytics group and brings more than 25 years of pharmaceutical industry experience across U.S. and global pricing, contracting, drug distribution, market research, and market access initiatives. His expertise spans real-world data and analytics, forecast and gross-to-net models, contract savings models, program ROI models, budget impact and cost-effectiveness modeling, and disease-market experience across both medical and pharmacy benefit products. Since joining eMAX Health in 2009, he has served as a subject matter expert across HEOR, market access, analytics, and payer account management.
Christian Bennett | Sr. Vice President, Market Access
Global market access • Pricing and reimbursement • Contracting strategy • Launch planning • Value development
Chris brings more than 25 years of healthcare consulting experience supporting pharmaceutical and biotechnology clients across U.S. and international market access strategy. His work spans global value development, pricing, reimbursement, contracting, and launch strategy across therapeutic areas including oncology, immunology, dermatology, CNS, endocrinology, cardiovascular, and rare/orphan diseases. Before joining eMAX Health, Chris served as Managing Director at a global consultancy, where he led a team of more than 100 market access professionals delivering high-impact access solutions.
Todd Reiter | Vice President
Market access • Reimbursement strategy • Payer engagement • Patient support • Commercialization • Launch planning
Todd brings more than 24 years of biopharma experience leading market access, reimbursement, payer engagement, and commercialization strategies across specialty, rare disease, CNS, mental health, and oncology portfolios. His expertise spans HEOR, pricing, contracting, patient services, field reimbursement, and launch planning. Before joining eMAX Health, Todd held senior market access and commercialization roles at bioMérieux, Citrus Health Group, Cencora, and Amgen, where he helped strengthen payer partnerships, reduce access barriers, and support successful product launches in complex therapeutic markets.
